Benitec Biopharma Inc.
BNTC
$13.75
$0.1050.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -94.44% | -107.14% |
| SG&A Expenses | 93.97% | 42.23% | 48.50% | 28.50% | -2.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.30% | -1.41% | 21.75% | -5.78% | 23.17% |
| Operating Income | -24.30% | 1.41% | -21.93% | 4.61% | -23.48% |
| Income Before Tax | -8.22% | 15.03% | -1.27% | 2.68% | -25.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.22% | 15.03% | -1.27% | 2.68% | -25.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.22% | 15.03% | -1.27% | 2.68% | -25.63% |
| EBIT | -24.30% | 1.41% | -21.93% | 4.61% | -23.48% |
| EBITDA | -24.40% | 1.52% | -21.93% | 4.48% | -24.08% |
| EPS Basic | 87.37% | 84.40% | 78.81% | 38.78% | 20.94% |
| Normalized Basic EPS | 87.37% | 82.78% | 81.27% | 38.72% | 20.91% |
| EPS Diluted | 87.37% | 84.40% | 78.81% | 38.78% | 20.94% |
| Normalized Diluted EPS | 87.37% | 82.78% | 81.27% | 38.72% | 20.91% |
| Average Basic Shares Outstanding | 756.86% | 393.46% | 440.60% | 58.95% | 58.90% |
| Average Diluted Shares Outstanding | 756.86% | 393.46% | 440.60% | 58.95% | 58.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |